Provided by Tiger Fintech (Singapore) Pte. Ltd.

HCW Biologics Inc.

0.2121
-0.0151-6.65%
Volume:94.03K
Turnover:20.60K
Market Cap:9.45M
PE:-0.27
High:0.2363
Open:0.2021
Low:0.2021
Close:0.2272
Loading ...

Company Profile

Company Name:
HCW Biologics Inc.
Exchange:
NASDAQ
Establishment Date:
2018
Employees:
36
Office Location:
2929 North Commerce Parkway,Miramar,Florida,United States
Zip Code:
33025
Fax:
954 842 2037
Introduction:
HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases. It also develops HCW9201, a cell-based therapy that is in Phase I clinical trials for the treatment of patients with relapsed/refractory acute myelogenous leukemia; and HCW9206, an injectable immunotherapeutic to use as adjuvant for adoptive cell therapy in cancer treatment. The company was incorporated in 2018 and is headquartered in Miramar, Florida.

Directors

Name
Position
Hing C. Wong
Chief Executive Officer and Director
Rick S. Greene
Director
Scott T. Garrett
Director

Shareholders

Name
Position
Hing C. Wong
Chief Executive Officer and Director
Lee Flowers
Senior Vice President of Business Development
Rebecca Byam
Chief Financial Officer
Jin an Jiao
Vice President of Development
Peter Rhode
Chief Scientific Officer and Vice President of Clinical Operations